XXII

22nd Century Group Inc (Ticker: XXII) is an innovative biopharmaceutical and agricultural leader dedicated to tobacco harm reduction through advanced genetic engineering. The company specializes in the development of low-nicotine tobacco products aimed at reducing nicotine addiction and enhancing public health. Additionally, 22nd Century is strategically diversifying into the burgeoning hemp and cannabis markets, aligning itself with the rapid growth of the legal cannabis sector. By prioritizing scientific research and regulatory compliance, 22nd Century presents a compelling investment opportunity for institutional investors interested in transformative, socially responsible sectors.